Cassipa Approved by FDA for Opioid Dependence

By |2018-09-12T15:28:07+00:00September 12th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

A new dosage strength of buprenorphine and naloxone sublingual film was approved recently by the Food and Drug Administration. Cassipa sublingual film, made by Teva Pharmaceuticals, is a 16 mg/4 mg dosage of buprenorphine and naloxone for the maintenance treatment of opioid dependence. Buprenorphine and naloxone sublingual film also is [...]

Seven-Year Analysis on Benzodiazepine Prescribing for Children, Adolescents, and Young Adults Showed Marked Increase

By |2018-08-09T08:01:59+00:00August 9th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

Conclusions The overall increase in prevalence rates of BZD dispensations during the study period and the unexpectedly high proportion of individuals who were prescribed a BZD on a long-term basis at a young age indicate a lack of congruence with international and national guidelines. These findings highlight the need for [...]

Alzheimer’s Agent, BAN2401, Shows Promise; Trial Design Hits Snag

By |2018-08-02T07:56:18+00:00August 2nd, 2018|Brief Bulletins from the Field, We Know Psychiatry|

A monoclonal antibody,BAN2401, that targets soluble amyloid-beta oligomers, slowed cognitive decline by up to 47% while clearing brain amyloid in 81% of patients with mild cognitive impairment and very mild Alzheimer’s disease, according to phase 2 study results. A joint venture with Esai and Biogen, BAN2401, is among the most promising [...]

Bipolar Medication, Lamictal, Linked with Serious Immune System Reaction

By |2018-06-29T07:28:14+00:00June 29th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

The Food and Drug Administration has issued a warning that the seizure and bipolar medication Lamictal (lamotrigine) can cause a rare but potentially life-threatening immune response. This life-threatening immune response, known as hemophagocytic lymphohistiocytosis (HLH), causes an uncontrolled immune response and can present as a persistent fever greater than 101° F. [...]

Effects of a depression-focused internet intervention in slot machine gamblers: A randomized controlled trial

By |2018-06-08T16:28:40+00:00June 8th, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|

By Lara Bücker , Julia Bierbrodt, Iver Hand, Charlotte Wittekind, and Steffen Moritz Background Problematic and pathological gambling have been linked to depression. Despite a high demand for treatment and negative financial consequences, only a small fraction of problematic and pathological gamblers seek professional help. The existing treatment gap could be narrowed by providing [...]

Alzheimer’s Therapy Elenbecestat Reduces Brain Amyloid Levels, Trial Shows, but Decline of Clinical Symptoms Still a Question

By |2018-06-08T08:10:58+00:00June 8th, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|

Treatment with the investigational compound elenbecestat reduced brain amyloid beta levels and was safe and well-tolerated, according to Phase 2 clinical trial results. The presence of amyloid beta plaques is a major characteristic of the brains of Alzheimer’s disease patients. Amyloid beta is produced through the work of a key enzyme called [...]

Esketamine nasal spray prevails in phase 3 trials

By |2018-06-06T07:29:40+00:00June 6th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

MIAMI — The combination of an esketamine nasal spray and an oral antidepressant may provide additional benefits for patients with treatment-resistant major depressive disorder, new research suggested. Two posters at a meeting of the American Society of Clinical Psychopharmacology, formerly known as the New Clinical Drug Evaluation Unit meeting, presented [...]

MDMA-Assisted Psychotherapy Improves PTSD

By |2018-06-05T15:12:24+00:00June 5th, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|

MIAMI — Adding methylenedioxymethamphetamine (MDMA), also known as ecstasy, to intensive psychotherapy appears to relieve posttraumatic stress disorder (PTSD), regardless of the cause, pooled data from six phase 2 studies show. The findings were presented at the American Society of Clinical Psychopharmacology (ASCP) 2018 annual meeting. The pooled data from the [...]

An Alzheimer’s Antibiotic Receives Initial Funding

By |2018-06-01T09:11:54+00:00June 1st, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|

Alzheimer’s disease startup Cortexyme was able to round up $76 million in funding for a potentially first-in-class treatment, while other companies are looking to move away from the field, according to a posting today on FierceBiotech. The healthy sum comes after the company completed an early safety study of its [...]